The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers

Sexually Transmitted Diseases

Volumn 42, Issue 3, 2015, Pages 143-152

  Borgdorff, Hanneke ^a   Verwijs, Marijn C ^a,b   Wit, Ferdinand W N M ^a   Tsivtsivadze, Evgeni ^c   Ndayisaba, Gilles F ^d   Verhelst, Rita ^e   Schuren, Frank H ^c   Van De Wijgert, Janneke H H M ^a,b,d  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c TNO   (Netherlands)

^d Rinda Ubuzima ^*  (Rwanda)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT; CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENITAL SYSTEM DISEASE ASSESSMENT; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; LEPTOTRICHIA; LEPTOTRICHIA AMNIONII; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYCOPLASMA; NUGENT SCORE; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PHYLOGENY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TEST; PREGNANT WOMAN; PREVOTELLA; PROSTITUTION; RWANDAN; SECONDARY ANALYSIS; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VAGINA CANDIDIASIS; VAGINA FLORA; WART VIRUS; CONDOM; IMMUNOLOGY; MICROBIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; RWANDA; SEXUALLY TRANSMITTED DISEASES; STATISTICS AND NUMERICAL DATA; UTERINE CERVIX; UTILIZATION; VAGINA;

ADULT; CERVIX UTERI; CONDOMS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; INCIDENCE; MICROARRAY ANALYSIS; PHYLOGENY; PREGNANCY; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; RWANDA; SEX WORKERS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; VAGINA;

EID: 84923698297     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000245     Document Type: Article

References (32)

1. United Nations Population Fund. The global programme to enhance reproductive health commodity security: annual report 2013. Available at: http://www.unfpa.org/public/home/.publications/pid/17481. Accessed November 23, 2014
2. Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIVacquisition in women: A systematic review of epidemiological evidence. Contraception 2014;90: 360-390
3. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011;65:302-307
4. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIVand other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009;23:263-284
5. Pettifor A, Delany S, Kleinschmidt I, et al. Use of injectable progestin contraception and risk of STI among South African women. Contraception 2009;80:555-560
6. Gursahaney PR, Meyn LA, Hillier SL, et al. Combined hormonal contraception may be protective against Neisseria gonorrhoeae infection. Sex Transm Dis 2010;37:356-360
7. Veldhuijzen NJ, Snijders PJ, Reiss P, et al. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010;10:862-874
8. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95
9. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007;21:1771-1777
10. van de Wijgert JH, Verwijs MC, Turner AN, et al. Hormonal contraception decreases risk of bacterial vaginosis but oral contraceptives may increase risk of vaginal candidiasis: implications for HIV transmission. AIDS 2013;27:2141-2153
11. Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: A systematic review and meta-Analysis. PLoS One 2013;8:e73055
12. Romero R, Hassan SS, Gajer P, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome 2014;2:4
13. Hayes RJ, Watson-Jones D, Celum C, et al. Treatment of sexually transmitted infections for HIV prevention. AIDS 2010;24(suppl 4): S15-S26
14. van de Wijgert JHHM, Borgdorff H, Verhelst R, et al. The vaginal microbiota: What have we learned after a decade of molecular characterization?. PLoS One 2014;9:e105998
15. Braunstein SL, Ingabire CM, Kestelyn E, et al. High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sex Transm Dis 2011;38:385-394
16. Borgdorff H, Tsivtsivadze E, Verhelst R, et al. Lactobacillusdominated cervicovaginal microbiome associated with reduced HIV/STI prevalence and genital HIV load in African women. ISME J 2014;8:1781-1793
17. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002;32:496-501
18. Oliveira FA, Ehrig V, Lang K, et al. Human papillomavirus genotype distribution and risk factors for infection in women from a small municipality in north east Brazil. Int J STD AIDS 2012; 23:e5-e10
19. Ozcan ES, Taskin S, Ortac F. High-risk human papillomavirus prevalence and its relation with abnormal cervical cytology among Turkish women. J Obstet Gynaecol 2011;31:656-658
20. Longatto-Filho A, Hammes LS, Sarian LO, et al. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest 2011;71:93-103
21. Maucort-Boulch D, PlummerM, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684-691
22. Bright PL, Norris Turner A, Morrison CS, et al. Hormonal contraception and area of cervical ectopy: A longitudinal assessment. Contraception 2011;84:512-519
23. De Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003;103:705-708
24. Mostad SB, Kreiss JK, Ryncarz AJ, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 2000;181:58-63
25. Cherpes TL, Melan MA, Kant JA, et al. Genital tract shedding of herpes simplex virus type 2 in women: Effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis 2005;40: 1422-1428
26. Kaushic C, Ashkar AA, Reid LA, et al. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003;77:4558-4565
27. Gillgrass AE, Ashkar AA, Rosenthal KL, et al. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol 2003;77:9845-9851
28. Glynn JR, Buve A, Carael M, et al. Decreased fertility among HIV-1-infected women attending antenatal clinics in three African cities. J Acquir Immune Defic Syndr 2000; 25:345-352
29. Bauters TG, Dhont MA, Temmerman MI, et al. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002;187:569-574
30. Aagaard K, Riehle K, Ma J, et al. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. PLoS One 2012;7:e36466. Doi: 10.1371/journal.pone.0036466
31. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:375-390
32. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: Individual participant data meta-Analysis. PLoS Med 2011;8:e1000416. doi: 10.1371/journal.pmed.1000416